Compare CSX Corporation (CSX) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Cassava Sciences Inc — how do they compare? CSX Corporation trades at $47.36 (market cap $86.70B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: CSX Corporation is far larger — about 2200.5× Cassava Sciences Inc's market cap, and CSX Corporation pays a 1.2% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Cassava Sciences Inc for 37 Days on average.
| CSX | FLNA | |
|---|---|---|
Market Cap | $86.70B | $39.40M |
Volume | 6,811,485 | 759,018 |
Sector | Industrials | Health |
52-Week High | $53.21 | $4.64 |
52-Week Low | $33.68 | $0.68 |
Typical Hold Time | 55 Days | 37 Days |
Enterprise Value | $104.66B | -$43.28M |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.34, down 0.34% today, with a bearish technical signal from moving averages. Recent earnings show mixed quarterly results, beating in Q1 and Q2 2026 but missing in Q4 2025. Revenue has declined from $14.9B in 2022 to $14.1B in 2025, though net income margin remains strong at 22.21%. Analyst consensus is bullish with a $51.00 price target, supported by institutional buying and positive news on dividend sustainability.
The outlook for CSX hinges on reversing revenue declines and executing on projected 2026 growth. Risks include competitive pressures and economic sensitivity, but strong profitability and analyst support offer upside. Investors should weigh valuation premiums against operational resilience in the freight sector.
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
